FMC Reports H1 2025 Results: New Products Key to Growth Amid Divergent Regional Performance

FMC, a leading global agricultural sciences company, recently disclosed its financial report for the second quarter and first half of 2025. The report indicates that despite facing multiple market challenges, the company achieved a slight revenue increase in the second quarter. However, its overall performance for the first half of the year declined, highlighting the divergent performance across its global regions.

First-Half Performance Overview: Volume Up, Prices Down, Revenue Under Pressure

In terms of overall performance, FMC's total revenue for the second quarter of 2025 was $1.051 billion, a year-over-year (YoY) increase of 1.2%. The primary driver of this growth was the strong sales momentum of new active ingredient products. However, this positive factor was partially offset by adjustments to a "cost-plus" contract with a diamide insecticide partner.

For the entire first half of the year, the company's total revenue was $1.841 billion, a decrease of 5.9% YoY. This decline reflects complex market dynamics: although global sales volume saw a solid 6% growth, it was insufficient to compensate for a 3% average price reduction due to market conditions and a 1% negative impact from foreign exchange fluctuations.

Regional Market Performance Analysis: EMEA Shines While Asia Faces Headwinds

Europe, Middle East, and Africa (EMEA): This region was the top performer, with second-quarter revenue surging 29.4% YoY to $260 million. Strong sales volume was the core engine of growth, driven particularly by strong demand for herbicides, diamide insecticide combination products, and cyantraniliprole products. This momentum successfully offset the low single-digit volume loss from planned product registration expiries.

Latin America: The market maintained steady growth, with quarterly revenue reaching $310 million, a modest increase of 1.0%. The strong performance in Brazil was the primary contributor, driven by the successful adoption of new active ingredients Fluindapyr and bixlozone.

North America: Revenue in the North American market saw a 5.3% decline, falling to $321 million. The decrease was primarily attributed to planned destocking by channel partners in Canada. Nevertheless, FMC's branded product sales in the U.S. recorded growth, and its biologicals business also performed well.

Asia: The Asian market faced the most significant challenges, with quarterly revenue dropping sharply by 16.8% YoY to $159 million. Persistent destocking pressure in India was the main reason for the shrinking sales volume, while the region also experienced a high single-digit price decline. The sole bright spot came from Australia, which achieved growth driven by the bixlozone herbicide.